Table 3.
Simple estimates of the number of adults with hepatitis B surface antigen (HBsAg) and hepatitis C virus (HCV) in WHO European Region
| Country | Population aged ⩾15 yr in 2008 | Prevalence in first time blood donors | Prevalence in studies representing general population | Prevalence in general population imputed from blood donors* | Prevalence estimate used | Estimated numbers with infection (rounded to nearest 100) | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| aged ⩾15 yr | HBsAg | Anti-HCV | HBsAg | Anti-HCV | HBsAg | Anti-HCV | HBsAg | Anti-HCV | HBsAg | Anti-HCV | Chronic HCV | |
| Those outside EU/EFTA | ||||||||||||
| Albania | 2 389 000 | 7·0% | 0·7% | 9·0% | 3·0% | 11% | 2·5% | Measured | Measured | 215 000 | 71 700 | 53 000 |
| Armenia | 2 431 000 | |||||||||||
| Azerbaijan | 6 549 000 | |||||||||||
| Belarus | 8 228 000 | |||||||||||
| Bosnia & Herzegovina | 3 170 000 | 0·1% | 0·03% | 0·1% | 0·1% | Imputed from BD | Imputed from BD | 4700 | 1900 | 1400 | ||
| Croatia | 3 760 000 | 0·2% | 0·1% | 0·3% | 0·2% | Imputed from BD | Imputed from BD | 10 200 | 7600 | 5600 | ||
| Georgia | 3 575 000 | 6·7% | Measured | 239 500 | 177 200 | |||||||
| Israel | 5 077 000 | 0·1% | 0·1% | 0·2% | 0·2% | Imputed from BD | Imputed from BD | 8300 | 10 400 | 7700 | ||
| Kazakhstan | 11 796 000 | 1·8% | 3·8% | 1·0% | 2·4% | Measured | Measured | 448 200 | 118 000 | 87 300 | ||
| Kyrgyzstan | 3 790 000 | 1·6% | Measured | 60 600 | 44 900 | |||||||
| Montenegro | 498 000 | 0·7% | 0·6% | 1·0% | 1·2% | Imputed from BD | Imputed from BD | 5000 | 5900 | 4400 | ||
| Republic of Moldova | 3 016 000 | |||||||||||
| Russian Federation | 120 185 000 | 1·1% | 2·1% | 1·5% | 3·6% | 1·5% | 4·3% | Measured | Measured | 1 802 800 | 4 326 700 | 3 201 700 |
| Serbia | 8 068 000 | 4·2% | 0·3% | 2·4% | 0·5% | 5·7% | 0·6% | Measured | Measured | 193 600 | 40 300 | 29 900 |
| Tajikistan | 4 239 000 | 3·0% | 2·9% | 0·5% | 4·1% | 5·9% | Imputed from BD | Measured | 171 800 | 21 200 | 15 700 | |
| FYR Macedonia | 1 674 000 | 1·0% | 0·2% | 1·4% | 0·5% | Imputed from BD | Imputed from BD | 22 800 | 7500 | 5600 | ||
| Turkey | 53 958 000 | 2·1% | 0·3% | 3·4% | 0·7% | 2·9% | 0·7% | Measured | Measured | 1 834 600 | 377 700 | 279 500 |
| Turkmenistan | 3 531 000 | |||||||||||
| Ukraine | 39 554 000 | 1·0% | 1·3% | 1·3% | 12% | 1·3% | 2·7% | Measured | Measured | 514 200 | 4 746 500 | 3 512 400 |
| Uzbekistan | 19 034 000 | 5·2% | 6·4% | 13·3% | 13·1% | 7·1% | 13% | Measured | Measured | 2 531 500 | 2 493 500 | 1 845 200 |
| Countries without HBsAg | 31 120 000 | 3·4% | Estimated from median prevalence | 1 058 100 | ||||||||
| Anti-HCV | 15 527 000 | 2·3% | Estimated from median prevalence | 357 100 | 264 300 | |||||||
| Total (rounded to nearest 1000) | 8 821 000 | 12 886 000 | 95 360 000 | |||||||||
| Those in EU/EFTA | ||||||||||||
| Austria | 7 087 000 | 0·1% | 0·1% | 0·3% | 0·5% | Imputed from BD | Imputed from BD | 24 300 | 37 900 | 28 000 | ||
| Belgium | 8 790 000 | 0·1% | 0·03% | 0·7% | 0·6% | 0·4% | 0·3% | Measured | Measured | 61 500 | 52 700 | 39 000 |
| Bulgaria | 6 606 000 | 1·8% | 0·4% | 1·3% | 7·9% | 4·5% | Imputed from BD | Measured | 520 800 | 85 900 | 63 500 | |
| Cyprus | 707 000 | 0·1% | 0·02% | 0·9% | 0·4% | 0·2% | Measured | Imputed from BD | 6400 | 1400 | 1 000 | |
| Czech Republic | 8 875 000 | 0·04% | 0·13% | 0·6% | 0·2% | 1·3% | Measured | Imputed from BD | 53 300 | 118 000 | 87 300 | |
| Denmark | 4 476 000 | 0·03% | 0·03% | 0·1% | 0·3% | Imputed from BD | Imputed from BD | 6100 | 12 400 | 9200 | ||
| Estonia | 1 140 000 | 0·3% | 0·7% | 1·2% | 7·0% | Imputed from BD | Imputed from BD | 13 600 | 79 600 | 58 900 | ||
| Finland | 4 403 000 | 0·03% | 0·04% | 0·2% | 0·1% | 0·4% | Measured | Imputed from BD | 8800 | 17 900 | 13 200 | |
| France | 50 870 000 | 0·03% | 0·02% | 1·3% | 0·1% | 0·2% | Imputed from BD | Measured | 61 400 | 661 300 | 489 400 | |
| Germany | 70 748 000 | 0·1% | 0·1% | 0·6% | 0·4% | 0·6% | 0·8% | Measured | Measured | 424 500 | 283 000 | 209 400 |
| Greece | 9 578 000 | 2·0% | 0·3% | 2·1% | 1·0% | 8·4% | 3·3% | Measured | Measured | 201 100 | 95 800 | 70 900 |
| Hungary | 8 511 000 | 0·0% | 0·3% | 0·0% | 3·1% | Imputed from BD | Imputed from BD | 2600 | 267 400 | 197 900 | ||
| Iceland | 249 000 | |||||||||||
| Ireland | 3 506 000 | 0·01% | 0·01% | 0·1% | 0·1% | 0·1% | Measured | Imputed from BD | 3500 | 3100 | 2300 | |
| Italy | 51 260 000 | 0·4% | 1·4% | 5·2% | 1·7% | Measured | Measured | 717 600 | 2 665 500 | 1 972 500 | ||
| Latvia | 1 943 000 | |||||||||||
| Lithuania | 2 823 000 | 0·6% | 1·0% | 2·6% | 10·3% | Imputed from BD | Imputed from BD | 73 900 | 289 800 | 214 500 | ||
| Luxembourg | 395 000 | 0·1% | 0·1% | 0·4% | 0·6% | Imputed from BD | Imputed from BD | 1700 | 2500 | 1800 | ||
| Malta | 342 000 | |||||||||||
| Netherlands | 13 553 000 | 0·1% | 0·02% | 0·1% | 0·4% | 0·3% | 0·2% | Measured | Measured | 13 600 | 54 200 | 40 100 |
| Norway | 3 862 000 | 0·03% | 0·03% | 0·1% | 0·4% | Imputed from BD | Imputed from BD | 4400 | 13 600 | 10 000 | ||
| Poland | 32 389 000 | 0·5% | 0·2% | 1·9% | 2·0% | 1·9% | Imputed from BD | Measured | 659 800 | 615 400 | 455 400 | |
| Portugal | 9 076 000 | 0·1% | 0·2% | 0·4% | 1·7% | Imputed from BD | Imputed from BD | 36 900 | 157 000 | 116 100 | ||
| Romania | 18 157 000 | 3·7% | 0·9% | 5·6% | 3·5% | 15·8% | 9·2% | Measured | Measured | 1 016 800 | 635 500 | 470 300 |
| Slovakia | 4 536 000 | 0·1% | 0·1% | 0·6% | 0·6% | 0·5% | Measured | Imputed from BD | 27 200 | 24 000 | 17 700 | |
| Slovenia | 1 733 000 | 0·1% | 0·03% | 0·4% | 0·4% | Imputed from BD | Imputed from BD | 7500 | 6100 | 4500 | ||
| Spain | 37 814 000 | 0·2% | 0·1% | 1·0% | 2·0% | 0·7% | 1·4% | Measured | Measured | 378 100 | 756 300 | 559 600 |
| Sweden | 7 641 000 | 0·05% | 0·1% | 0·2% | 0·4% | 0·2% | 0·6% | Measured | Measured | 15 300 | 30 600 | 22 600 |
| Switzerland | 6 335 000 | 0·2% | 0·1% | 0·7% | 0·6% | Imputed from BD | Imputed from BD | 44 800 | 40 600 | 30 000 | ||
| United Kingdom | 50 210 000 | 0·04% | 0·04% | 0·7% | 0·2% | 0·4% | Imputed from BD | Measured | 86 400 | 351 500 | 260 100 | |
| Countries without HbsAg | 2 534 000 | 0·6% | Estimated from median prevalence | 15 200 | ||||||||
| Anti-HCV | 2 534 000 | 1·2% | Estimated from median prevalence | 29 100 | 21 600 | |||||||
| Total (rounded to nearest 1000) | 4 487 000 | 7 387 900 | 5 467 000 | |||||||||
| Total Europe 732 137 000 | 13 308 000 | 20 274 000 | 15 003 000 | |||||||||
| 1·8% | 2·8% | 2·0% | ||||||||||
BD, Blood donors; FYR Macedonia, Former Yugoslav Republic of Macedonia; Anti-HCV, antibodies to the hpatitis C virus; EU/EFTA, European Union and European Free Trade Association area.
*
Estimated using median of the national ratios of the general population prevalence to prevalence in blood donors.